<DOC>
	<DOCNO>NCT00019032</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness monoclonal antibody therapy treat patient chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate toxicity murine monoclonal antibody Mik-beta-1 ( MOAB Mik-beta-1 ) patient T-cell large granular lymphocytic leukemia associate granulocytopenia , anemia , thrombocytopenia . - Determine clinical response patient treated drug . - Assess effect drug number circulate CD3+ , CD8+ express granular lymphocyte number polymorphonuclear leukocyte , red blood cell , platelet patient population . - Monitor patient time course decline circulate infused MOAB Mik-beta-1 production human antibody IV infuse murine MOAB Mik-beta-1 . OUTLINE : This dose-escalation study . Patients receive monoclonal antibody Mik-beta-1 ( MOAB Mik-beta-1 ) IV 2 hour day 1 , 4 , 7 , 10 . Patients achieve complete response ( CR ) partial response ( PR ) may receive 1 additional course begin sooner 4 week completion first course , absence antibody MOAB Mik-beta-1 . Treatment continue absence disease progression , unacceptable toxicity , severe allergic reaction . Cohorts 3-6 patient receive escalate dos MOAB Mik-beta-1 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients follow 6-10 day 4-6 week therapy . Patients PR CR may follow every 6 month 2 year relapse . All patient follow survival . PROJECTED ACCRUAL : A maximum 25 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Tcell large granular lymphocytic ( TLGL ) leukemia associate clinically significant hematocytopenia demonstrate one follow value growth factor support : Absolute neutrophil count less 1,000/mm^3 Hemoglobin less 8 g/dL Platelet count le 50,000/mm^3 Clinically evaluable disease peripheral blood TLGL leukemia cell express CD3+ , CD8+ phenotype detectable FACS Monoclonal Tcell population peripheral blood ( circulate mononuclear cell ) demonstrate TCR beta gamma chain gene rearrangement PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % Life expectancy : More 2 month Hematopoietic : See Disease Characteristics No active major bleed episode within past 4 week Hepatic : Direct bilirubin le 1.5 mg/dL Renal : Creatinine le 2.0 mg/dL Other : No concurrent serious active infection Patients fever without apparent site infection may begin study antibiotic long follow true : No pathogenic organism culture Afebrile ( maximum temperature le 38Â°C ) least 5 day HIV negative No primary cancer basal cell skin cancer Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior interferon Concurrent filgrastim ( GCSF ) , sargramostim ( GMCSF ) , interleukin11 , similar sustainedrelease/longacting product ( e.g. , pegylated GCSF ) allow dose establish least 4 week prior study participation No concurrent interferon Chemotherapy : At least 4 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : Concurrent corticosteroid allow dose establish least 3 week prior study participation Radiotherapy : Not specify Surgery : Not specify Other : At least 1 week since completion prior antibiotic regimen serious infectious episode No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
</DOC>